StockpollyBeta
Get App
Popularity #656
BBIO · NASDAQ · Biotechnology

BridgeBio Pharma (BBIO)

Develops and commercializes genetically targeted medicines through a decentralized portfolio model.

$69.31
After hours+0.07 (+0.10%)
At close$69.24(+4.00%)

  1. BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

    Seeking Alpha

  2. VIRGINIA RETIREMENT SYSTEMS ET Al Invests $715,000 in BridgeBio Pharma, Inc. $BBIO

    Defense World

  3. BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

    Seeking AlphaEarnings

  4. BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Seeking AlphaEarnings

  5. Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

    GlobeNewsWireClinical

  6. Frazier Life Sciences Management L.P. Sells 1,900,000 Shares of BridgeBio Pharma, Inc. $BBIO

    Defense WorldOwnership

  7. BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

    GlobeNewsWireClinical

  8. BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

    GlobeNewsWireOther

  9. Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

    GlobeNewsWireClinical

  10. BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

    GlobeNewsWireClinical

  11. BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

    Zacks Investment ResearchEarnings

  12. Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

    Zacks Investment ResearchMarket move

  13. BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

    GlobeNewsWireClinical

  14. BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

    The Motley Fool

  15. BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

    GlobeNewsWire

  16. BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

    GlobeNewsWire

  17. BridgeBio Pharma Q2 Earnings Call Highlights

    Defense World

  18. BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

    Zacks Investment Research

  19. BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months

    Seeking Alpha

  20. BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

    Seeking Alpha